PLYMOUTH
MEETING, Pa., Dec. 3, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY),
today announced that Harmony's management team will participate in
a fireside chat at the upcoming Oppenheimer Movers in Rare Disease
Summit in New York, NY on
Thursday, December 12, 2024, at
9:00 a.m. ET.
A webcast of the fireside chat will be available on the investor
page of Harmony's website at
https://ir.harmonybiosciences.com/.
About Harmony Biosciences
Harmony
Biosciences is a pharmaceutical company dedicated to
developing and commercializing innovative therapies for patients
with rare neurological diseases who have unmet medical needs.
Driven by novel science, visionary thinking, and a commitment to
those who feel overlooked, Harmony Biosciences is
nurturing a future full of therapeutic possibilities that may
enable patients with rare neurological diseases to truly thrive.
Established by Paragon Biosciences, LLC, in 2017 and
headquartered in Plymouth Meeting, Pa, we believe that when
empathy and innovation meet, a better future can begin; a vision
evident in the therapeutic innovations we advance, the culture we
cultivate, and the community programs we foster. For more
information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-539-9700
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harmony-biosciences-to-participate-in-oppenheimer-movers-in-rare-disease-summit-302320185.html
SOURCE Harmony Biosciences
